Combination therapy with carboplatin and thalidomide suppresses tumor growth and metastasis in 4T1 murine breast cancer model

Souza, Cristina Maria de; Silva, Ana Cândida Araújo e; Ferraciolli, Clarissa Jesus; Moreira, Giovanna Vieira; Campos, Leonardo; Reis, Diego Carlos dos; Lopes, Míriam Teresa Paz; Ferreira, Mônica Alves Neves Diniz; Andrade, Sílvia Passos; Cassali, Geovanni Dantas

doi:10.1016/j.biopha.2013.08.004

Cited by 26 publications

(21 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4TI breast cancer cells (ATCC, Manassas, VA), which were radiation and paraplatin sensitive [19,20], and EMT-6 tumors (ATCC, Manassas, VA), which were radiation and paraplatin resistant [21,22], were used in this study. 4TI cells were maintained in RPMI 1640 medium (Gibco N.Y. USA) containing 10% fetal bovine serum (FBS).…”

Section: Tumor Cells and Experimental Animal Tumor Medelsmentioning

confidence: 99%

See 1 more Smart Citation

Targeted concurrent chemoradiotherapy, by using improved microcapsules that release carboplatin in response to radiation, improves detectability by computed tomography as well as antitumor activity while reducing adverse effect in vivo

Harada¹,

Ehara²,

Ishii³

et al. 2015

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Section: Tumor Cells and Experimental Animal Tumor Medelsmentioning

confidence: 99%

“…Carboplatin is an analogue of paraplatin [19][20][21][22]. In this study, microcapsules that release carboplatin in response to radiation were prepared using alginate polymerized with Fe 2+ and hyaluronic acid.…”

mentioning

confidence: 99%

Targeted concurrent chemoradiotherapy, by using improved microcapsules that release carboplatin in response to radiation, improves detectability by computed tomography as well as antitumor activity while reducing adverse effect in vivo

Harada¹,

Ehara²,

Ishii³

et al. 2015

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

“…High-quality trials are needed to evaluate the efficacy of chemotherapy protocols as well as to provide guidance for treating high-risk mammary gland tumours (Sorenmo 2003, Sorenmo and others 2013). Previous studies evaluating thalidomide in the 4T1 mice mammary tumour model have demonstrated a clear benefit in controlling primary tumour development, as well as metastatic progression (De Souza and others 2012, De Souza and others 2014, Dos Reis and others 2014). Two pilot studies involving thalidomide were performed in veterinary medicine: thalidomide induced prolonged responses as a single drug in canine haemangiosarcomas (Woods and others 2004), and a multimodal approach including bleomycin, piroxican, thalidomide, radiotherapy and surgery was considered to have encouraging results in feline unresectable head and neck squamous cell carcinomas (Marconato and others 2013).…”

Section: Introductionmentioning

confidence: 97%

Absence of significant adverse events following thalidomide administration in bitches diagnosed with mammary gland carcinomas

et al. 2016

View full text Add to dashboard Cite

The aim of the study was to evaluate the incidence of adverse events (AEs) in female dogs diagnosed with advanced clinical stage mammary gland neoplasms following treatment with thalidomide. A prospective analysis of 29 female dogs treated with a high dose (HD) of 20 mg/kg/day of thalidomide for three months followed by a low dose (LD) of 10 mg/kg/day of thalidomide for three months was performed. All patients underwent physical examination, complete blood count, serum biochemistry profile, thoracic radiographs, and abdominal ultrasound analysis before the treatment and after the HD and LD. Clinical AEs were absent in 16/29 (55.17 per cent) patients following HD. An initial 3-5 day period of somnolence was described in 4/29 (13.79 per cent), prolonged somnolence in 5/29 (17.24 per cent), a short period of somnolence lasting only a few hours in 3/29 (10.34 per cent), and difficulty to rouse was described in 5/29 (17.24 per cent) cases. Two patients (6.89 per cent) presented with prolonged somnolence that interfered with activities of daily living, resulting in anticipation of the dose reduction to the proposed LD after 15 days of the HD treatment. Following dose reduction, AE improvement was observed in all patients. Albeit remaining within the reference ranges, erythrocytes, haematocrit, total leucocyte count, neutrophils, lymphocytes, monocytes and γ-glutamyltranspeptidase showed significant alteration associated to thalidomide treatment.

show abstract

“…Subsequently, it was revealed in 1999 that THD can be used in the treatment of multiple myeloma (7). In the following years, a large number of studies revealed that THD exerted an antitumor effect in several types of cancer, including prostate, colorectal, non-small-cell lung and breast cancer, and renal cell carcinoma (8)(9)(10)(11)(12). The invasion and metastasis of tumors depends on the process of angiogenesis, and THD may be able to inhibit the growth of tumor tissue by preventing the development of the necessary blood vessels.…”

Section: Introductionmentioning

confidence: 99%

Effect of thalidomide in combination with gemcitabine on human pancreatic carcinoma SW-1990 cell lines in vitro and in vivo

Qiao¹,

Yuan²,

Shen³

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. Pancreatic cancer is one of the most frequently occurring malignancies worldwide and it is the fourth most common cause of cancer-associated mortality in Western countries. Thalidomide (THD) plays an important role in tumor therapy, as it is able to promote early stage apoptosis and inhibit the process of angiogenesis. The present study evaluated the ability of the combination of THD and gemcitabine (GEM) to inhibit the growth of the pancreatic cancer SW-1990 cell line in vitro and in vivo. Early apoptosis in the SW-1990 cells was detected by the Annexin V/propidium iodide double staining method, the level of B-cell lymphoma 2 (Bcl-2) and Bcl-2-associated X protein (Bax) were detected by reverse transcription-polymerase chain reaction (RT-PCR) and western blot analysis. In addition, the expression of vascular endothelial growth factor in transplanted tumor tissue was measured by RT-PCR, immunohistochemistry and western blot analysis. Cluster of differentiation 34 positivity was considered to indicate the microvessel density. Subsequent to treatment with THD and GEM alone or in combination, it was found that the expression of Bax was upregulated, while the expression of Bcl-2 was downregulated, and the growth of SW-1990 cells and transplanted tumors in nude mice was evidently inhibited. The administration of THD in combination with GEM may demonstrate a potent antitumor effect that increases with increasing dose. The mechanism behind the antitumor effect may be associated with the inhibition of tumor angiogenesis and induction of the apoptosis pathway.

show abstract

Combination therapy with carboplatin and thalidomide suppresses tumor growth and metastasis in 4T1 murine breast cancer model

Cited by 26 publications

References 27 publications

Targeted concurrent chemoradiotherapy, by using improved microcapsules that release carboplatin in response to radiation, improves detectability by computed tomography as well as antitumor activity while reducing adverse effect in vivo

Targeted concurrent chemoradiotherapy, by using improved microcapsules that release carboplatin in response to radiation, improves detectability by computed tomography as well as antitumor activity while reducing adverse effect in vivo

Absence of significant adverse events following thalidomide administration in bitches diagnosed with mammary gland carcinomas

Effect of thalidomide in combination with gemcitabine on human pancreatic carcinoma SW-1990 cell lines in vitro and in vivo

Contact Info

Product

Resources

About